Does the media refer more to NUVB or CRNX?

In the previous week, Nuvation Bio and Nuvation Bio both had 12 articles in the media. Nuvation Bio's average media sentiment score of 0.88 beat Crinetics Pharmaceuticals' score of 0.68 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PTGX or NUVB?

In the previous week, Protagonist Therapeutics had 2 more articles in the media than Nuvation Bio. MarketBeat recorded 14 mentions for Protagonist Therapeutics and 12 mentions for Nuvation Bio. Protagonist Therapeutics' average media sentiment score of 1.58 beat Nuvation Bio's score of 0.88 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 13 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nuvation Bio 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, TGTX or NUVB?

TG Therapeutics has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $616.29M 12.92 $447.18M $2.86 18.19 Nuvation Bio $62.90M 35.02 -$204.63M -$0.43 N/A

Does the media favor TGTX or NUVB?

In the previous week, Nuvation Bio had 6 more articles in the media than TG Therapeutics. MarketBeat recorded 12 mentions for Nuvation Bio and 6 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.97 beat Nuvation Bio's score of 0.88 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvation Bio 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, NUVB or QGEN?

Qiagen has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvation Bio $62.90M 35.02 -$204.63M -$0.43 N/A Qiagen $2.10B 4.08 $424.88M $1.91 21.76

Is NUVB or QGEN more profitable?

Qiagen has a net margin of 19.16% compared to Nuvation Bio's net margin of -102.06%. Qiagen's return on equity of 14.40% beat Nuvation Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nuvation Bio -102.06% -44.10% -23.80% Qiagen 19.16% 14.40% 8.40%

Does the media refer more to NUVB or QGEN?

In the previous week, Nuvation Bio had 4 more articles in the media than Qiagen. MarketBeat recorded 12 mentions for Nuvation Bio and 8 mentions for Qiagen. Qiagen's average media sentiment score of 1.18 beat Nuvation Bio's score of 0.88 indicating that Qiagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NUVB or APGE?

In the previous week, Nuvation Bio had 4 more articles in the media than Apogee Therapeutics. MarketBeat recorded 12 mentions for Nuvation Bio and 8 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.96 beat Nuvation Bio's score of 0.88 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Nuvation Bio (NUVB) Competitors

$6.33 0.00 (-0.06%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$6.33 +0.00 (+0.06%)

As of 07/31/2026 07:40 PM Eastern

Compare

NUVB vs. CRNX, PTGX, TGTX, QGEN, and APGE

Should you buy Nuvation Bio stock or one of its competitors? MarketBeat compares Nuvation Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvation Bio include Crinetics Pharmaceuticals (CRNX), Protagonist Therapeutics (PTGX), TG Therapeutics (TGTX), Qiagen (QGEN), and Apogee Therapeutics (APGE).

How does Nuvation Bio compare to Crinetics Pharmaceuticals?

Nuvation Bio (NYSE:NUVB) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, Nuvation Bio and Nuvation Bio both had 12 articles in the media. Nuvation Bio's average media sentiment score of 0.88 beat Crinetics Pharmaceuticals' score of 0.68 indicating that Nuvation Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio has a net margin of -102.06% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Nuvation Bio has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	35.02	-$204.63M	-$0.43	N/A
Crinetics Pharmaceuticals	$18.07M	487.37	-$465.32M	-$5.13	N/A

Nuvation Bio has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Nuvation Bio presently has a consensus price target of $12.88, suggesting a potential upside of 103.53%. Crinetics Pharmaceuticals has a consensus price target of $81.00, suggesting a potential downside of 3.02%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Summary

Nuvation Bio beats Crinetics Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Nuvation Bio compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Nuvation Bio (NYSE:NUVB) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Protagonist Therapeutics presently has a consensus target price of $123.00, indicating a potential downside of 9.98%. Nuvation Bio has a consensus target price of $12.88, indicating a potential upside of 103.53%. Given Nuvation Bio's higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Protagonist Therapeutics has higher revenue and earnings than Nuvation Bio. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	118.65	-$130.15M	-$1.81	N/A
Nuvation Bio	$62.90M	35.02	-$204.63M	-$0.43	N/A

Protagonist Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

In the previous week, Protagonist Therapeutics had 2 more articles in the media than Nuvation Bio. MarketBeat recorded 14 mentions for Protagonist Therapeutics and 12 mentions for Nuvation Bio. Protagonist Therapeutics' average media sentiment score of 1.58 beat Nuvation Bio's score of 0.88 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	13 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Nuvation Bio	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio has a net margin of -102.06% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Nuvation Bio	-102.06%	-44.10%	-23.80%

Summary

Protagonist Therapeutics beats Nuvation Bio on 12 of the 17 factors compared between the two stocks.

How does Nuvation Bio compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Nuvation Bio (NYSE:NUVB) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

TG Therapeutics has a net margin of 65.95% compared to Nuvation Bio's net margin of -102.06%. TG Therapeutics' return on equity of 88.73% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Nuvation Bio	-102.06%	-44.10%	-23.80%

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

TG Therapeutics has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	12.92	$447.18M	$2.86	18.19
Nuvation Bio	$62.90M	35.02	-$204.63M	-$0.43	N/A

TG Therapeutics has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

TG Therapeutics currently has a consensus price target of $58.50, indicating a potential upside of 12.44%. Nuvation Bio has a consensus price target of $12.88, indicating a potential upside of 103.53%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts clearly believe Nuvation Bio is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Nuvation Bio had 6 more articles in the media than TG Therapeutics. MarketBeat recorded 12 mentions for Nuvation Bio and 6 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.97 beat Nuvation Bio's score of 0.88 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvation Bio	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Nuvation Bio on 9 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to Qiagen?

Nuvation Bio (NYSE:NUVB) and Qiagen (NYSE:QGEN) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, Nuvation Bio had 4 more articles in the media than Qiagen. MarketBeat recorded 12 mentions for Nuvation Bio and 8 mentions for Qiagen. Qiagen's average media sentiment score of 1.18 beat Nuvation Bio's score of 0.88 indicating that Qiagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a net margin of 19.16% compared to Nuvation Bio's net margin of -102.06%. Qiagen's return on equity of 14.40% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Qiagen	19.16%	14.40%	8.40%

Qiagen has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	35.02	-$204.63M	-$0.43	N/A
Qiagen	$2.10B	4.08	$424.88M	$1.91	21.76

Nuvation Bio currently has a consensus target price of $12.88, suggesting a potential upside of 103.53%. Qiagen has a consensus target price of $43.34, suggesting a potential upside of 4.29%. Given Nuvation Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Nuvation Bio is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Qiagen	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nuvation Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

Summary

Qiagen beats Nuvation Bio on 10 of the 17 factors compared between the two stocks.

How does Nuvation Bio compare to Apogee Therapeutics?

Nuvation Bio (NYSE:NUVB) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Nuvation Bio has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	35.02	-$204.63M	-$0.43	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Nuvation Bio had 4 more articles in the media than Apogee Therapeutics. MarketBeat recorded 12 mentions for Nuvation Bio and 8 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.96 beat Nuvation Bio's score of 0.88 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio presently has a consensus price target of $12.88, suggesting a potential upside of 103.53%. Apogee Therapeutics has a consensus price target of $121.25, suggesting a potential downside of 9.57%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Nuvation Bio is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Nuvation Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Apogee Therapeutics has a net margin of 0.00% compared to Nuvation Bio's net margin of -102.06%. Apogee Therapeutics' return on equity of -32.64% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Summary

Nuvation Bio beats Apogee Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Nuvation Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUVB vs. The Competition

Export

Metric	Nuvation Bio	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.20B	$3.54B	$6.86B	$23.66B
Dividend Yield	N/A	3.78%	2.59%	4.21%
P/E Ratio	-14.71	7.38	282.30	31.00
Price / Sales	35.02	1,182.44	561.34	81.85
Price / Cash	N/A	44.80	28.60	18.73
Price / Book	7.19	16.96	10.98	4.76
Net Income	-$204.63M	-$12.56M	$3.49B	$1.07B
7 Day Performance	-4.80%	-1.76%	-0.60%	-0.34%
1 Month Performance	11.28%	-8.38%	-5.20%	-0.53%
1 Year Performance	184.95%	48.40%	62.01%	19.19%

Nuvation Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUVB Nuvation Bio	3.6448 of 5 stars	$6.33 -0.1%	$12.88 +103.5%	+185.0%	$2.20B	$62.90M	N/A	60	Upcoming Earnings Gap Up
CRNX Crinetics Pharmaceuticals	2.1458 of 5 stars	$83.85 +0.1%	$78.27 -6.7%	+200.0%	$8.83B	$7.70M	N/A	210	Upcoming Earnings
PTGX Protagonist Therapeutics	1.5588 of 5 stars	$135.56 -0.4%	$123.00 -9.3%	+153.8%	$8.75B	$46.02M	N/A	120	Positive News Upcoming Earnings
TGTX TG Therapeutics	3.147 of 5 stars	$55.75 -0.5%	$58.50 +4.9%	+48.6%	$8.58B	$616.29M	19.49	290	Gap Up
QGEN Qiagen	3.9249 of 5 stars	$41.05 -0.8%	$43.34 +5.6%	-20.9%	$8.53B	$2.09B	21.44	5,654	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NUVB) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvation Bio (NUVB) Competitors

NUVB vs. CRNX, PTGX, TGTX, QGEN, and APGE

How does Nuvation Bio compare to Crinetics Pharmaceuticals?

Summary

How does Nuvation Bio compare to Protagonist Therapeutics?

Summary

How does Nuvation Bio compare to TG Therapeutics?

Summary

How does Nuvation Bio compare to Qiagen?

Summary

How does Nuvation Bio compare to Apogee Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvation Bio (NUVB) Competitors

NUVB vs. CRNX, PTGX, TGTX, QGEN, and APGE

How does Nuvation Bio compare to Crinetics Pharmaceuticals?

Does the media refer more to NUVB or CRNX?

Is NUVB or CRNX more profitable?

Do insiders & institutionals have more ownership in NUVB or CRNX?

Which has higher earnings & valuation, NUVB or CRNX?

Which has more risk & volatility, NUVB or CRNX?

Do analysts recommend NUVB or CRNX?

Summary

How does Nuvation Bio compare to Protagonist Therapeutics?

Do insiders and institutionals believe in PTGX or NUVB?

Do analysts recommend PTGX or NUVB?

Which has better earnings & valuation, PTGX or NUVB?

Which has more risk and volatility, PTGX or NUVB?

Does the media prefer PTGX or NUVB?

Is PTGX or NUVB more profitable?

Summary

How does Nuvation Bio compare to TG Therapeutics?

Is TGTX or NUVB more profitable?

Do insiders & institutionals believe in TGTX or NUVB?

Which has higher valuation & earnings, TGTX or NUVB?

Which has more risk & volatility, TGTX or NUVB?

Do analysts recommend TGTX or NUVB?

Does the media favor TGTX or NUVB?

Summary

How does Nuvation Bio compare to Qiagen?

Does the media refer more to NUVB or QGEN?

Is NUVB or QGEN more profitable?

Which has stronger valuation & earnings, NUVB or QGEN?

Do analysts rate NUVB or QGEN?

Do institutionals and insiders have more ownership in NUVB or QGEN?

Which has more volatility and risk, NUVB or QGEN?

Summary

How does Nuvation Bio compare to Apogee Therapeutics?

Which has better earnings and valuation, NUVB or APGE?

Do institutionals & insiders have more ownership in NUVB or APGE?

Does the media refer more to NUVB or APGE?

Do analysts rate NUVB or APGE?

Which has more risk & volatility, NUVB or APGE?

Is NUVB or APGE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools